HomeInsightsPE

Orchid Pharma Ltd PE Ratio

Orchid Pharma Ltd PE Ratio

stocks purchased

₹ 1.0 Cr

Volume transacted

stocks purchased

7.5 K

stocks traded

Last Updated time: 13 Oct 9.00 AM

Image

Orchid Pharma Ltd

NSE: ORCHPHARMA

PE

63.2

Last updated: 13 Oct 9.00 AM

Key Highlights

  • The P/E Ratio of Orchid Pharma Ltd is 63.2 as of 13 Oct 9.00 AM.
  • The P/E Ratio of Orchid Pharma Ltd changed from 0.7 on March 2019 to 57.5 on March 2024 . This represents a CAGR of 108.49% over 6 years. .
  • The Latest Trading Price of Orchid Pharma Ltd is ₹ 1389 as of 11 Oct 15:30.
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.2. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 158.1. The PE Ratio of Textiles industry is 37.6. In 2024.

Historical P/E Ratio of Orchid Pharma Ltd

No data available

Company Fundamentals for Orchid Pharma Ltd

No data available

Image

Orchid Pharma Ltd

NSE: ORCHPHARMA

PRICE

1389.25

0.00 (0.00%)

stock direction

Last updated: 11 Oct 15:30

Market price Over Time

1M

1Y

3Y

5Y

Monitoring Orchid Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPriceleft
11 Oct 20241389.25
10 Oct 20241389.25
09 Oct 20241372.05
08 Oct 20241340.65
07 Oct 20241256.75
04 Oct 20241284.15
03 Oct 20241291.2
01 Oct 20241333.95
30 Sep 20241367.95
27 Sep 20241421.05

SWOT Analysis Of Orchid Pharma Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Orchid Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Orchid Pharma Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Orchid Pharma Ltd637,046
Sun Pharmaceuticals Industries Ltd434,56,342
Divis Laboratories Ltd971,63,028
Cipla Ltd291,28,827
Torrent Pharmaceuticals Ltd701,18,373
Mankind Pharma Ltd571,11,956

Key Valuation Metric of Orchid Pharma Ltd

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Orchid Pharma Ltd

No data available

* All values are in crore

Historical Revenue of Orchid Pharma Ltd

No data available

* All values are in crore

Historical EBITDA of Orchid Pharma Ltd

No data available

* All values are in crore

Historical Net Profit of Orchid Pharma Ltd

No data available

* All values are in crore

Historical Dividend Payout of Orchid Pharma Ltd

No data available

* All values are in %

About Orchid Pharma Ltd

  • Orchid Pharma Ltd., is one of the leading pharmaceutical companies in India head quartered in Chennai and involved in development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals with exports spanning over 40 countries.
  • Orchid's world class manufacturing infrastructure include USFDA compliant API and Finished Dosage Form facilities at Chennai in India.
  • The Company has dedicated state-of-art and GLP compliant R&D infrastructure for Process Research, Drug Discovery and Pharmaceutical Research at Chennai. The Company is a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well as in drug discovery, which was incorporated on 1st July 1992 as a 100% Export Oriented Unit (EOU).

Orchid Pharma Ltd News Hub

News

Orchid Pharma announces board meeting date

Orchid Pharma will hold a meeting of the Board of Directors of the Company on 12 August 20...

Read more

10 Aug 202412:49

News

Orchid Pharma to conduct AGM

Orchid Pharma announced that the Annual General Meeting (AGM) of the company will be held ...

Read more

18 Jul 202420:35

News

Orchid Pharma partners with Cipla for pan-India distribution of Cefepime-Enmetazobactam

Cefepime-Enmetazobactam has been approved for the treatment of complicated urinary tract i...

Read more

29 Jun 202410:08

News

Orchid Pharma partners with Cipla to launch antibiotic drug - Cefepime-Enmetazobactam in India

Orchid Pharma announced the launch of its new drug - Cefepime-Enmetazobactam, which has be...

Read more

28 Jun 202419:23

News

Orchid Pharma receives DCGI approval for Enmetazobactam

Orchid Pharma has received Drugs Controller General of India (DCGI) approval for the manuf...

Read more

06 Jun 202413:06

News

Orchid Pharma gains on DCGI nod for new antibiotic drug combination

DCGI has also granted permission to manufacture and market finished dosage form (FDF) of C...

Read more

06 Jun 202412:38

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

FAQs for PE of Orchid Pharma Ltd

What is the current PE Ratio of Orchid Pharma Ltd?

The Current PE Ratio of Orchid Pharma Ltd is 63.18 as on 13 Oct 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 13 Oct 2024.

What was the PE Ratio of Orchid Pharma Ltd last year?

The PE Ratio of Orchid Pharma Ltd was 33.87 last year, now the PE ratio is 63.18, showing a year-on-year growth of 86.5%.

What does the PE Ratio of Orchid Pharma Ltd indicate about its stock?

The PE Ratio of Orchid Pharma Ltd is 63.18. This ratio indicates that investors are willing to pay 63.18 times the earnings per share for each share of Orchid Pharma Ltd.

What is the PE Ratio Growth of Orchid Pharma Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Orchid Pharma Ltd grew by 86.5% whereas, the EPS ratio grew by -15.0.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*